Related Experiment Video
Updated: May 29, 2026
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Differential treatment effects across subgroups in immunomodulatory drugs for sepsis: protocol for a systematic
Ling Ding1,2,3,4, Chunyang Bai5, Linge Jian6
1Department of Critical Care Medicine, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Introduction:
Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection, may benefit from immunomodulatory drugs. Nevertheless, numerous clinical trials of these drugs have failed to demonstrate efficacy, partly due to substantial heterogeneous treatment responses. Subgroup analyses from these trials are frequently employed to investigate different treatment effects across subgroups. However, which drugs might have different effects across subgroups and how credible these findings are have not been well summarised and evaluated. Additionally, the differences in the characteristics and results of subgroup analyses based on whether the primary trial's main effect is statistically significant remain unclear. We will conduct a systematic review to comprehensively address these questions.
Methods And Analysis:
We will include randomised controlled trials (RCTs) evaluating immunomodulatory drugs for adult sepsis and exclude quasi-randomised trials, single-arm studies, animal research, conference abstracts, study protocols and non-English publications. To comprehensively search for subgroup analyses, we will search both RCTs and their published secondary analyses across PubMed, Embase, Web of Science, ClinicalTrials.gov and the Cochrane Library from their inception. Four reviewers will independently screen eligible studies and only one subgroup analysis will be selected for data extraction using standardised forms. The credibility of subgroup effects will be assessed using the Instrument for assessing the Credibility of Effect Modification Analyses. We will analyse the proportion and characteristics of subgroup analyses reported in trials. We will qualitatively summarise the results of subgroup analyses, focusing on findings with a subgroup-specific p value<0.05 or an interaction p value<0.05. If two or more studies examined the same drug within a subgroup, we will perform data synthesis using a random-effects model to estimate pooled subgroup effects. We will compare the differences based on whether the primary trial's main effect was statistically significant using t-tests, Mann-Whitney U tests, χ2 test or Fisher's exact test, as appropriate.
Ethics And Dissemination:
No ethical approval is required because the data we will use do not include individual patient data. Findings will be disseminated through publication in a peer-reviewed journal.
Trial Registration Number:
CRD420251089737.
